Tabelle mega trials cardiologici:
parametri di *effect size*: RR, ARR, NNT.

Legenda

- **Condition**: criteri di inclusione
- **pts**: numero di individui coinvolti nello studio
- **Treat:** gruppo di trattamento in studio
- **Contr**: gruppo di controllo
- **Endpoint**: endpoint primario
- **Follow up**: durata media del tempo di follow up in cui è stato valutato l'endpoint primario
- **RR**: Rischio Relativo
- **RRR**: Riduzione percentuale del rischio relativo
- **p**: significatività statistica della differenza riscontrata fra i due gruppi
- **ARR**: riduzione assoluta del rischio espressa in percentuale
- **NNT**: numero di individui da trattare per ottenere un beneficio (reciproco di ARR *100)

Per ogni studio sono riportati l'anno, la rivista di pubblicazione ed i principali parametri sopra elencati, che riassumono le evidenze emerse.
Da notare, nel caso di una differenza significativa fra i due gruppi di trattamento e controllo, l'entità della riduzione assoluta del rischio e il valore di NNT.
La maggior parte di questi studi ha modificato le procedure di trattamento precedentemente utilizzate nella pratica clinica.

STEMI											
Trial	**condition**	**pts**	**treat**	**contr**	**endpoint**	**follow up**	**RR**	**RRR**	**p**	**ARR**	**NNT**
GISSI Lancet feb 1986	STEMI	11.712	SK	std	death	21 days	0,81	**19%**	0,0002	2,2	**45**
ISIS-2 Lancet aug 1988	STEMI suspect	17.187	SK ASA	placebo	death	5 weeks	0,58	**42%**	<0,0001	5,3	**19**
GISSI-2 Lancet jul 1990	STEMI	12.490	tPA	SK	composite	in H	1,04	**-4%**	ns	0,6	**167**
GUSTO NEJM sep 1993	STEMI	41.021	tPA	SK	death	30 days	0,86	**14%**	0,001	1,0	**100**
Keeley Lancet Jan 4, 2003 ***quantitative review of 23 trials***	STEMI	7.739	pPCI	fibrinolytic	death	4-6 weks	0,73	**27%**	0,000	2,0	**50**

Statins											
Trial	**condition**	**pts**	**treat**	**contr**	**endpoint**	**follow up**	**RR**	**RRR**	**p**	**ARR**	**NNT**
4S Lancet Nov 19, 1994	CAD	4.444	simva	placebo	death	5.4 y	0,70	**30%**	0.0003	4,0	**25**
Woscops NEJM Nov 16, 1995	dislip no CAD	6.595 men	prava	placebo	death	4.9 y	0,69	**31%**	<0,001	2,4	**42**
HPS Lancet jul 2002	CAD, oad, diabetes	20.536	simva	placebo	death any vasc	5 y	0,87 0,76	**13%** **24%**	0,0003	1,8 5,4	**56** **19**
PROVE-IT NEJM apr 2004	ACS	4.162	atorva	prava	composite	2 y	0,84	**16%**	0,005	3,9	**26**
Jupiter NEJM nov 2008	app. healthy	17.802	rosuva	placebo	composite	1,9 y	0,57	**43%**	<0,0001	1,2	**83**

P2Y12 inhibitors

Trial	condition	pts	treat	contr	endpoint	follow up	HR	RRR	p	ARR	NNT
Triton-TIMI 38 NEJM Nov 2007	ACS-PCI	13.608	prasugrel	clopidogrel	cv death, MI, stroke	14.5 m	0,81	19%	0,001	2,2	45
Triton-STEMI Lancet Feb 2009	STEMI	3.534	prasugrel	clopidogrel	cv death, MI, stroke	15 months	0,79	21%	0,02	2,4	42
PLATO NEJM Sep 2009	ACS	18.624	ticagrelor	clopidogrel	cv death, MI, stroke	12 months	0,84	16%	< 0,001	1,9	53
PLATO CKD Circ Sep 2010	ACS CKD CrCl < 60	3.237	ticagrelor	clopidogrel	cv death, MI, stroke	12 months	0,77	23%		4,7	21
PLATO PCI Lancet Jan 2010	ACS-PCI	13.408	ticagrelor	clopidogrel	cv death, MI, stroke	12 months	0,84	16%	0,002	1,7	59
PLATO noPCI BMJ Jun 2011	ACS noPCI	5.216	ticagrelor	clopidogrel	cv death, MI, stroke	12 months	0,85	15%	0,04	2,3	43
Trilogy NEJM Aug 2012	NSTE noPCI	7.243	prasugrel	clopidogrel	cv death, MI, stroke	17 months	0,91	9%	0,21	2,1	48
Champion **Phoenics** NEJM Mar 2013	PCI	11.145	cangrelor iv bolus	clopidogrel os load	composite	48 h	0,78	22%	0,005	1,2	83

Oral anticoagulants											
Trial	**condition**	**pts**	**treat**	**contr**	**endpoint**	**follow up**	**RR**	**RRR**	**p**	**ARR**	**NNT**
RE-LY NEJM aug 2009	atrial fib	18.113	dabigatran 150 mg	warfarin	stroke/ embolism	2 y	0,66	**34%**	0,001 for sup	0,6	**172**
Rocket AF NEJM sep 2011	atrial fib	14.264	rivaroxaban	warfarin	stroke/ embolism	2 y	0,79	**21%**	0,001 for noninf	0,5	**200**
Aristotle NEJM sep 2011	atrial fib	18.201	apixaban	warfarin	stroke/ embolism	1,8 y	0,79	**21%**	0,001 for noninf	0,3	**303**

Bivalirudin												
Trial	**RR ischemic***	p	ARR	NNT	**RR bleeding***	p	ARR	NNT	**RR NACE**	p	ARR	NNT
Replace-2 Jama Feb 2003 6010 pts	1.09	0,40	0.5	200	0,41	0.01	1.7	59	0,92	0,32	0,8	125
Acuity NEJM Nov 2006 13819 pts	1.08	0,3	0.5	200	0,53	0,001	2,7	37	0,86	0.02	1,6	62
Horizons-Ami NEJM May 2008 3602 pts	0.99	0,95	0.1	1000	0,6	0,001	3,4	29	0,76	0,005	2,9	34
Euromax ** NEJM Oct 2013 2218 pts	1,09	0,6	0,5	200	0,43	0,001	3,4	29	0,60	0,001	3,4	29
Heat-PPCI *** Lancet Jul 2914 1812 pts	1,52	0,01	3,0	33	1,15	0,59	0,4	250				

* Primary efficacy outcome: composite of ischemic adverse events. Primary safety outcome: bleeding.
** Acute stent thrombosis was higher with bivalirudin (1.1% vs. 0.2%)
*** Bivalirudin infusion only during the duration of PPCI, instead of at least 4 hours after PCI.

Radial											
Trial	**condition**	**pts**	**treat**	**contr**	**endpoint**	**follow up**	**RR**	**RRR**	**p**	**ARR**	**NNT**
Rival Lancet apr 2011	ACS	7.021	radial	femoral	composite	30 days	0,92	8%	0,5	0,3	333
STEMI: 28% ; anti IIb/IIIa: **25%**; radial PCI > 70/y = 66%; mortality: 1.3%; bleeding: 0.4%											
Rifle-STEACS JACC aug 2012	STEMI	1.001	radial	femoral	NACE	30 days	0,65	35%	0,003	7,4	14
anti IIb/IIIa: **69%**; radial PCI > 50%; cardiogenic shock: 6.1%; Rescue: 7.6%; mortality: 7.2%; bleeding: 10%.											
Rival STEMI JACC oct 2012	STEMI	1.958	radial	femoral	composite	30 days	0,6	40%	0,026	2,1	48

References

1. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (**GISSI**). [No authors listed] Lancet. 1986 Feb 22;1(8478):397-402.
2. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: **ISIS-2**. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. [No authors listed] Lancet. 1988 Aug 13;2(8607): 349-60.
3. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The **GUSTO** investigators. [No authors listed] N Engl J Med. 1993 Sep 2;329(10):673-82.
4. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Keeley EC1, Boura JA, Grines CL. Lancet. 2003 Jan 4;361(9351):13-20.
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastati**n** Survival Study (**4S**) [No authors listed] Lancet. 1994 Nov 19;344(8934):1383-9.
6. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. **WOSCOPS** N Engl J Med. 1995 Nov 16;333(20):1301-7.
7. MRC/BHF **H**eart **P**rotection **S**tudy of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Heart Protection Study Collaborative Group. **HPS** Lancet. 2002 Jul 6;360(9326):7-22.
8. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504
   PROVE-IT Medline
9. Cannon CP, et al.; **IMPROVE-IT** Investigators. IMPROVE-IT trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Program and abstracts of the 2014 American Heart Association Scientific Sessions; November 15-19, 2014; Chicago, Illinois. Abstract LBCT-02.
10. O'Riordan M. **IMPROVE-IT**: 'Modest' benefit when adding ezetimibe to statins in post-ACS patients. November 21, 2014. http://www.medscape.com/viewarticle/835030 Accessed December 5, 2014.
11. Prasugrel versus clopidogrel in patients with acute coronary syndromes. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; **TRITON-TIMI 38** Investigators. N Engl J Med. 2007 Nov 15;357(20):2001-15. Epub 2007 Nov 4.

12. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, et al. (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045–1057 **PLATO** [PubMed]
13. Effect of platelet inhibition with cangrelor during PCI on ischemic events.Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimský P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA; **CHAMPION PHOENIX** Investigators. N Engl J Med. 2013 Apr 4;368(14):1303-13. doi: 10.1056/NEJMoa1300815. Epub 2013 Mar 10.
14. Dabigatran versus warfarin in patients with atrial fibrillation. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; **RE-LY** Steering Committee and Investigators. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.
15. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D., Daniel E. Singer, M.D., Werner Hacke, M.D., Ph.D., Günter Breithardt, M.D., Jonathan L. Halperin, M.D., Graeme J. Hankey, M.D., Jonathan P. Piccini, M.D., Richard C. Becker, M.D., Christopher C. Nessel, M.D., John F. Paolini, M.D., Ph.D., Scott D. Berkowitz, M.D., Keith A.A. Fox, M.B., Ch.B., Robert M. Califf, M.D., and the **ROCKET AF** Steering Committee for the ROCKET AF Investigators N Engl J Med 2011; 365:883 891 September 8, 2011 DOI: 10.1056/NEJMoa1009638 N Engl J Med 2011;365:883-891 Free Full Text | Web of Science | Medline
16. Apixaban versus warfarin in patients with atrial fibrillation. Granger CB, Alexander JH, McMurray JJV, et al. **Aristotle** N Engl J Med 2011; 365:981-992September 15, 2011DOI: 10.1056/NEJMoa1107039 Free Full Text | Web of Science | Medline
17. **Table trials**
18. **Excel: trials**